What is Aligos Therapeutics, Inc. Common Stock's Market Cap?

Aligos Therapeutics, Inc. Common Stock's Market Cap is $71.9M, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's Enterprise Value?

Aligos Therapeutics, Inc. Common Stock's Enterprise Value is $41.6M, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's Price / Sales?

Aligos Therapeutics, Inc. Common Stock's Price / Sales is 19.2×, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's EV / Revenue?

Aligos Therapeutics, Inc. Common Stock's EV / Revenue is 11.1×, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's EV / EBITDA?

Aligos Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's Revenue (TTM)?

Aligos Therapeutics, Inc. Common Stock's Revenue (TTM) is $3.7M, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's Net Income (TTM)?

Aligos Therapeutics, Inc. Common Stock's Net Income (TTM) is -$76.0M, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's EBITDA?

Aligos Therapeutics, Inc. Common Stock's EBITDA is -$77.9M, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?

Aligos Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -6.08, based on as-reported figures from SEC (XBRL) filings.

What is Aligos Therapeutics, Inc. Common Stock's EBITDA Margin?

Aligos Therapeutics, Inc. Common Stock's EBITDA Margin is -2083.3%, based on as-reported figures from SEC (XBRL) filings.

Aligos Therapeutics, Inc. Common Stock (ALGS) Financial Statements

Aligos Therapeutics, Inc. Common Stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00QX7QH77

XNAS · usd

5.76▼ 0.45 (-7.25%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close6.21

Day's Range5.62 – 6.34

52-Week Range3.98 – 13.69

Volume63.6K

Avg Volume113.7K

Share Statistics

Shares Outstanding

Employees82

ExchangeXNAS

Listed2020-10-16

Share count as of August 3, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Aligos Therapeutics, Inc. Common Stock (ALGS)

What is Aligos Therapeutics, Inc. Common Stock's Market Cap?: Aligos Therapeutics, Inc. Common Stock's Market Cap is $71.9M, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's Enterprise Value?: Aligos Therapeutics, Inc. Common Stock's Enterprise Value is $41.6M, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's Price / Sales?: Aligos Therapeutics, Inc. Common Stock's Price / Sales is 19.2×, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's EV / Revenue?: Aligos Therapeutics, Inc. Common Stock's EV / Revenue is 11.1×, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's EV / EBITDA?: Aligos Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's Revenue (TTM)?: Aligos Therapeutics, Inc. Common Stock's Revenue (TTM) is $3.7M, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's Net Income (TTM)?: Aligos Therapeutics, Inc. Common Stock's Net Income (TTM) is -$76.0M, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's EBITDA?: Aligos Therapeutics, Inc. Common Stock's EBITDA is -$77.9M, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?: Aligos Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -6.08, based on as-reported figures from SEC (XBRL) filings.
What is Aligos Therapeutics, Inc. Common Stock's EBITDA Margin?: Aligos Therapeutics, Inc. Common Stock's EBITDA Margin is -2083.3%, based on as-reported figures from SEC (XBRL) filings.